Cardiff Oncology
Open
$1.56
Prev. Close
$1.56
High
$1.56
Low
$1.55
Market Snapshot
$105.28M
-2.4
-0.94
$684K
31
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2004-07-27. The firm's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The firm's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2004-07-27. The firm's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The firm's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.
Recently from Cashu
Cardiff Oncology Files Legal Action Against Nerviano Medical over Onvansertib Licensing Dispute
Cardiff Oncology Inc (Ticker: CRDF) navigates a critical legal landscape as it announces the initiation of legal proceedings against Nerviano Medical Sciences. This significant action arises from Nerv…
Cardiff Oncology (CRDF) Advances Precision Cancer Care Amid Market Challenges
Cardiff Oncology Advances Cancer Treatment Amid Market Challenges Cardiff Oncology Inc. (CRDF) is making strides in the fight against metastatic colorectal cancer (mCRC) with its ongoing CRDF-004 Phas…
Cardiff Oncology (CRDF) Advances Targeted Therapy for Metastatic Colorectal Cancer with CRDF-004 Trial
Cardiff Oncology Advances in Metastatic Colorectal Cancer Research Cardiff Oncology, Inc. (CRDF) is making significant strides in the field of cancer treatment, particularly with its recent developmen…
Cardiff Oncology (CRDF) Innovates Metastatic Colorectal Cancer Treatment with Promising Clinical Trial Results
Cardiff Oncology's Innovative Approach to Metastatic Colorectal Cancer Treatment Cardiff Oncology, Inc. (CRDF) stands at the forefront of advancements in cancer treatment, particularly focusing on met…